Inclusion body myositis: Treatment with intravenous immunoglobulin

A. A. Amato, R. J. Barohn, Carlayne E Jackson, E. J. Pappert, Z. Sahenk, J. T. Kissel

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

We report the results of nine patients with inclusion body myositis treated with intravenous immunoglobulin in an open-label uncontrolled study. None of our patients improved on objective manual muscle testing or functional disability scores. One patient developed mild neutropenia, complicating the intravenous immunoglobulin treatment. Our results do not exclude the possibility that intravenous immunoglobulin could be beneficial in some patients by slowing the rate of deterioration or perhaps stabilizing the disease. However, given the lack of objective improvement and high cost of treatment, we would not recommend intravenous immunoglobulin in the treatment of inclusion body myositis unless a blinded, controlled trial demonstrates clear benefit.

Original languageEnglish (US)
Pages (from-to)1516-1518
Number of pages3
JournalNeurology
Volume44
Issue number8
StatePublished - Aug 1994

Fingerprint

Inclusion Body Myositis
Intravenous Immunoglobulins
Therapeutics
Neutropenia
Health Care Costs
Muscles

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Amato, A. A., Barohn, R. J., Jackson, C. E., Pappert, E. J., Sahenk, Z., & Kissel, J. T. (1994). Inclusion body myositis: Treatment with intravenous immunoglobulin. Neurology, 44(8), 1516-1518.

Inclusion body myositis : Treatment with intravenous immunoglobulin. / Amato, A. A.; Barohn, R. J.; Jackson, Carlayne E; Pappert, E. J.; Sahenk, Z.; Kissel, J. T.

In: Neurology, Vol. 44, No. 8, 08.1994, p. 1516-1518.

Research output: Contribution to journalArticle

Amato, AA, Barohn, RJ, Jackson, CE, Pappert, EJ, Sahenk, Z & Kissel, JT 1994, 'Inclusion body myositis: Treatment with intravenous immunoglobulin', Neurology, vol. 44, no. 8, pp. 1516-1518.
Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: Treatment with intravenous immunoglobulin. Neurology. 1994 Aug;44(8):1516-1518.
Amato, A. A. ; Barohn, R. J. ; Jackson, Carlayne E ; Pappert, E. J. ; Sahenk, Z. ; Kissel, J. T. / Inclusion body myositis : Treatment with intravenous immunoglobulin. In: Neurology. 1994 ; Vol. 44, No. 8. pp. 1516-1518.
@article{227030a5aceb4905b433cbe7bce7eff7,
title = "Inclusion body myositis: Treatment with intravenous immunoglobulin",
abstract = "We report the results of nine patients with inclusion body myositis treated with intravenous immunoglobulin in an open-label uncontrolled study. None of our patients improved on objective manual muscle testing or functional disability scores. One patient developed mild neutropenia, complicating the intravenous immunoglobulin treatment. Our results do not exclude the possibility that intravenous immunoglobulin could be beneficial in some patients by slowing the rate of deterioration or perhaps stabilizing the disease. However, given the lack of objective improvement and high cost of treatment, we would not recommend intravenous immunoglobulin in the treatment of inclusion body myositis unless a blinded, controlled trial demonstrates clear benefit.",
author = "Amato, {A. A.} and Barohn, {R. J.} and Jackson, {Carlayne E} and Pappert, {E. J.} and Z. Sahenk and Kissel, {J. T.}",
year = "1994",
month = "8",
language = "English (US)",
volume = "44",
pages = "1516--1518",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Inclusion body myositis

T2 - Treatment with intravenous immunoglobulin

AU - Amato, A. A.

AU - Barohn, R. J.

AU - Jackson, Carlayne E

AU - Pappert, E. J.

AU - Sahenk, Z.

AU - Kissel, J. T.

PY - 1994/8

Y1 - 1994/8

N2 - We report the results of nine patients with inclusion body myositis treated with intravenous immunoglobulin in an open-label uncontrolled study. None of our patients improved on objective manual muscle testing or functional disability scores. One patient developed mild neutropenia, complicating the intravenous immunoglobulin treatment. Our results do not exclude the possibility that intravenous immunoglobulin could be beneficial in some patients by slowing the rate of deterioration or perhaps stabilizing the disease. However, given the lack of objective improvement and high cost of treatment, we would not recommend intravenous immunoglobulin in the treatment of inclusion body myositis unless a blinded, controlled trial demonstrates clear benefit.

AB - We report the results of nine patients with inclusion body myositis treated with intravenous immunoglobulin in an open-label uncontrolled study. None of our patients improved on objective manual muscle testing or functional disability scores. One patient developed mild neutropenia, complicating the intravenous immunoglobulin treatment. Our results do not exclude the possibility that intravenous immunoglobulin could be beneficial in some patients by slowing the rate of deterioration or perhaps stabilizing the disease. However, given the lack of objective improvement and high cost of treatment, we would not recommend intravenous immunoglobulin in the treatment of inclusion body myositis unless a blinded, controlled trial demonstrates clear benefit.

UR - http://www.scopus.com/inward/record.url?scp=0027935703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027935703&partnerID=8YFLogxK

M3 - Article

C2 - 8058161

AN - SCOPUS:0027935703

VL - 44

SP - 1516

EP - 1518

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -